Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $2.42 down -1.22% from its previous closing price of $2.45. In other words, the price has decreased by -$1.22 from its previous closing price. On the day, 9.08 million shares were traded. IOVA stock price reached its highest trading level at $2.5 during the session, while it also had its lowest trading level at $2.35.
Ratios:
For a deeper understanding of Iovance Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.27. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 875686720 and an Enterprise Value of 627671424. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.63 while its Price-to-Book (P/B) ratio in mrq is 1.18. Its current Enterprise Value per Revenue stands at 2.599 whereas that against EBITDA is -1.668.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.83, which has changed by -0.78734624 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 3.80%, while the 200-Day Moving Average is calculated to be -44.94%.
Shares Statistics:
For the past three months, IOVA has traded an average of 17.10M shares per day and 12827680 over the past ten days. A total of 341.92M shares are outstanding, with a floating share count of 292.73M. Insiders hold about 19.10% of the company’s shares, while institutions hold 56.83% stake in the company. Shares short for IOVA as of 1755216000 were 71364792 with a Short Ratio of 4.17, compared to 1752537600 on 98633209. Therefore, it implies a Short% of Shares Outstanding of 71364792 and a Short% of Float of 21.440001.
Earnings Estimates
A detailed examination of Iovance Biotherapeutics Inc (IOVA) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.12 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$1.0 and -$1.25 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$0.66, with 10.0 analysts recommending between -$0.42 and -$0.97.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $76.19M this quarter.It ranges from a high estimate of $84.2M to a low estimate of $70M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $58.55MFor the next quarter, 11 analysts are estimating revenue of $88.56M. There is a high estimate of $106.71M for the next quarter, whereas the lowest estimate is $75.88M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300M, while the lowest revenue estimate was $255.73M, resulting in an average revenue estimate of $275.57M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $436.22M in the next fiscal year. The high estimate is $540.4M and the low estimate is $350M.
